Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance

Antiviral Res. 2016 Jul:131:1-8. doi: 10.1016/j.antiviral.2016.04.002. Epub 2016 Apr 4.

Abstract

Background: Human cytomegalovirus (HCMV) drug-resistance remains of high clinical importance. While UL97-mutations can confer ganciclovir-resistance, UL54-mutations can be associated with resistance to ganciclovir, foscarnet and/or cidofovir.

Objective: Three UL97-mutations (A619V, P468Q, del597-599), three UL54-mutations (V715A, A492D, L516W) and two UL97/UL54-mutation combinations (A594TUL97+V715MUL54; A591VUL97+D515EUL54, L516MUL54, I521TUL54) were characterised phenotypically. All mutations were introduced into the bacterial artificial chromosome (BAC) TB40-BACKL7-UL32EGFP. A revertant of HCMV-TB40-BACKL7-UL32EGFP/A591VUL97+D515EUL54, L516MUL54, I521TUL54 was generated.

Results: The UL97-mutation del597-599 showed GCV-resistance while A619V and P468Q were drug-sensitive. The UL54-mutation V715A was FOS-resistant/CDV-hypersensitive and L516W was GCV/CDV cross-resistant. Mutation A594TUL97+V715MUL54 showed GCV/FOS cross-resistance. HCMV-BACKL7-UL32EGFP/A591VUL97+D515EUL54,L516MUL54, I521TUL54 was GCV/CDV cross-resistant with a remarkably increased GCV-ratio compared to a strain where only the UL54-mutations D515E+L516M+I521T were present. Since the revertant was drug-sensitive again, the increased drug-ratio is supposed to be due to the UL97-polymorphism A591V.

Conclusion: Phenotypic characterisation of newly detected mutations in UL97 and UL54 remain of high importance. Only mutations with a confirmed phenotype allow reliable interpretation of genotypic methods. Here, we provide the first description of a UL97-polymorphism that contributes to the overall drug-resistance when combined with resistance-associated UL54-mutations. The finding shows the high importance to look at mutations in the context of their genetic background.

Keywords: Antiviral drug-resistance; Cytomegalovirus; Infections in immunocompromised patients; Polymorphisms with phenotypic impact.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Antiviral Agents / pharmacology*
  • Child
  • Chromosomes, Artificial, Bacterial
  • Cidofovir
  • Cytomegalovirus / drug effects
  • Cytomegalovirus / genetics*
  • Cytomegalovirus / growth & development
  • Cytomegalovirus Infections / congenital
  • Cytomegalovirus Infections / virology
  • Cytosine / analogs & derivatives
  • Cytosine / pharmacology
  • DNA, Viral
  • DNA-Directed DNA Polymerase / genetics*
  • Drug Resistance, Viral / genetics*
  • Foscarnet / pharmacology
  • Ganciclovir / pharmacology
  • Genotype
  • Humans
  • Immunocompromised Host
  • Infant
  • Middle Aged
  • Mutation
  • Organophosphonates / pharmacology
  • Phenotype
  • Phosphotransferases (Alcohol Group Acceptor) / genetics*
  • Polymorphism, Genetic*
  • Viral Proteins / genetics*

Substances

  • Antiviral Agents
  • DNA, Viral
  • Organophosphonates
  • UL54 protein, Human herpesvirus 5
  • Viral Proteins
  • Foscarnet
  • Cytosine
  • Phosphotransferases (Alcohol Group Acceptor)
  • ganciclovir kinase
  • DNA-Directed DNA Polymerase
  • Cidofovir
  • Ganciclovir